» Articles » PMID: 18313151

APOBEC and INOS Are Not the Main Intracellular Effectors of IFN-gamma-mediated Inactivation of Hepatitis B Virus Replication

Overview
Journal Antiviral Res
Publisher Elsevier
Date 2008 Mar 4
PMID 18313151
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aim: Interferon-gamma (IFN-gamma) produced by activated T-cells is the principle mediator of non-cytolytic Hepatitis B virus (HBV) inactivation; however the intracellular pathways responsible are poorly defined. We investigated the role of IFN-gamma-inducible nitric oxide synthase (iNOS) and APOBEC3 (A3) enzyme family in the inhibition of HBV replication by IFN-gamma.

Methods: Hepatoma-cell lines transfected with HBV DNA were treated with IFN-gamma. Viral replication, iNOS and A3 mRNAs were quantitated by TaqManPCR and the direct nitric oxide (NO) effect on HBV replication was investigated using an NO-donor. A3G antiviral activity was verified by co-transfection with its inhibitor, human immunodeficiency virus (HIV)-associated virion infectivity factor (Vif).

Results: IFN-gamma caused a dose-dependent reduction (>50%) of HBV DNA in the absence of cytotoxicity. Although iNOS mRNA increased 45-fold in IFN-gamma treated cells, NO2- was not detectable in supernatants and the use of an NO-donor did not inhibit HBV replication. A3 enzyme mRNAs varied between cells and were >10-fold higher in lymphocytes than in liver tissue. IFN-gamma up-regulated A3G mRNA by three-fold, associated with significant HBV DNA decrease. However, A3G degradation by Vif did not abolish the antiviral effect of IFN-gamma against HBV.

Conclusions: IFN-gamma inhibits HBV replication and up-regulates both iNOS and A3G. However, other pathways appear to have a greater role in IFN-gamma-induced HBV inactivation in the liver.

Citing Articles

Surface Display of Duck Hepatitis A Virus Type 1 VP1 Protein on Bacillus subtilis Spores Elicits Specific Systemic and Mucosal Immune Responses on Mice.

Chen B, Yang Y, Wang Z, Dai X, Cao Y, Zhang M Probiotics Antimicrob Proteins. 2024; .

PMID: 39002060 DOI: 10.1007/s12602-024-10323-2.


IFN-γ: A Crucial Player in the Fight Against HBV Infection?.

Hillaire M, Lawrence P, Lagrange B Immune Netw. 2023; 23(4):e30.

PMID: 37670813 PMC: 10475827. DOI: 10.4110/in.2023.23.e30.


Novel therapeutic strategies for chronic hepatitis B.

Phillips S, Jagatia R, Chokshi S Virulence. 2022; 13(1):1111-1132.

PMID: 35763282 PMC: 9272843. DOI: 10.1080/21505594.2022.2093444.


Roles of APOBEC3 in hepatitis B virus (HBV) infection and hepatocarcinogenesis.

Zhang Y, Chen X, Cao Y, Yang Z Bioengineered. 2021; 12(1):2074-2086.

PMID: 34043485 PMC: 8806738. DOI: 10.1080/21655979.2021.1931640.


Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.

Phillips S, Chokshi S, Chatterji U, Riva A, Bobardt M, Williams R Gastroenterology. 2014; 148(2):403-14.e7.

PMID: 25305505 PMC: 7172380. DOI: 10.1053/j.gastro.2014.10.004.